REGN4461
REGN4461
LEPR Antibody
Lipodystrophy and obesity
A POWERFUL RESEARCH AND
DEVELOPMENT ENGINE
Our robust pipeline of investigational product candidates strives to address many serious medical conditions including asthma, pain, cancer and infectious diseases.
-
Phase 1 Trials
Cemiplimab* PD-1 Antibody
CEMIPLIMAB*
PD-1 AntibodyCancerREGN1979 CD20/CD3 Antibody
REGN1979
CD20 X CD3 AntibodyCancerREGN3767*
REGN3767*
LAG-3 AntibodyCancerCEMIPLIMAB + REGN1979
CEMIPLIMAB + REGN1979
PD-1 Antibody + CD20 X CD3 AntibodyCancerCEMIPLIMAB + REGN3767
CEMIPLIMAB + REGN3767*
PD-1 Antibody + LAG3 AntibodyCancerREGN3470-3471-3479 Antibody to Ebola virus
REGN3470-3471-3479
Antibody to Ebola virusEbola virus infectionREGN3048-3051
REGN3048-3051
Antibody to Middle Eastern Respiratory CoronavirusMERS-CoV infectionREGN2477 + TREVOGRUMAB
REGN2477 + TREVOGRUMAB
Activin A Antibody + GDF8 AntibodyMuscle-wasting diseasesREGN1908-1909
REGN1908-1909
Fel d 1 AntibodyAllergic diseasesREGN3918
REGN3918
C5 AntibodyParoxysmal nocturnal hemoglobinuria -
Phase 1 Trials
EVINACUMAB 2
EVINACUMAB
ANGPTL-3 AntibodyRefractory hypercholesterolemia (both HeFH and non-FH)DUPILUMAB* IL-4R Antibody
DUPILUMAB*
IL-4R AntibodyEosinophilic esophagitisSARILUMAB* IL-6R Antibody
SARILUMAB*
IL-6R AntibodyPolyarticular-course juvenile idiopathic arthritisCemiplimab* PD-1 Antibody
CEMIPLIMAB*
PD-1 AntibodyCutaneous squamous cell carcinoma, basal cell carcinomaREGN2477
REGN2477
Activin A AntibodyFibrodysplasia Ossificans Progressiva (FOP)REGN3500
REGN3500*
IL-33 AntibodyAsthma -
Phase 1 Trials
ALIROCUMAB* PCSK9 Antibody
ALIROCUMAB*
PCSK9 AntibodyHypercholesterolemia, LDL cholesterol reduction and prevention of cardiovascular eventsDUPILUMAB* IL-4R Antibody
DUPILUMAB*
IL-4R AntibodyAtopic dermatitis in pediatrics and adolescents, asthma in adults and adolescents, pediatric asthma, nasal polypsEVINACUMAB Angptl3 Antibody
EVINACUMAB
ANGPTL-3 AntibodyHomozygous familial hypercholesterolemia (HoFH)AFLIBERCEPT^ VEGF-Trap
AFLIBERCEPT
VEGF-TrapNon-proliferative diabetic retinopathy (NPDR) without DMEFASINUMAB† NGF Antibody
FASINUMAB†
NGF AntibodyOsteoarthritis pain, chronic lower back painCemiplimab* PD-1 Antibody
CEMIPLIMAB*
PD-1 AntibodyNon-small cell lung cancer, cervical cancer
Trials Footnotes
* in collaboration with Sanofi
* in collaboration with Sanofi
† in collaboration with Teva and Mitsubishi Tanabe
† in collaboration with Teva and Mitsubishi Tanabe
This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.